Answers are grounded in this paper and cite their sources.
Pure red cell aplasia (PRCA) is a clinically important manifestation of T-cell large granular lymphocytic leukemia (T-LGLL), yet severe erythroid failure may occur when the circulating clone is small and conventional leukemic thresholds are not met. We review evidence suggesting possible biological links among reactive cytotoxic T-cell expansion, T-cell clones of uncertain significance, low-burden clonal disease, and overt T-LGLL, with PRCA highlighting the clinical significance of clonal T-cell pathogenicity. STAT3/JAK-STAT activation, apoptosis resistance, cytotoxic effector programs, antigen-driven T-cell receptor selection, marrow inflammation, and host clonal hematopoiesis provide complementary mechanisms. Causal attribution should integrate confirmed PRCA, exclusion of competing causes, immunophenotypic and T-cell receptor clonality, and appropriately interpreted molecular findings. Cyclosporine and cyclophosphamide remain central therapies; methotrexate is phenotype-dependent, whereas sirolimus and JAK inhibition are rational options for refractory disease. Future studies should prioritize clone-resolved multi-omics, standardized response endpoints, and prospective molecularly stratified registries. This framework prioritizes pathogenicity over numerical clone burden.
No takes yet. Share an insight, caveat, or question.
Qin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: